Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
Discover how our symposium brought NHS and industry together to discuss the future of healthcare. We focused on innovation, collaboration, and transformation.
Iain Shield (Associate Director – Market Access, Mtech Access) discusses updates to prescribing information (Clause 12) in the ABPI Code of Practice and the considerations for digital materials